Literature DB >> 30107497

Immune checkpoint inhibitors myocarditis: not all cases are clinically patent.

Constance Thibault1, Yann Vano1, Gilles Soulat2,3,4, Mariana Mirabel3,4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30107497     DOI： 10.1093/eurheartj/ehy485

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  10 in total

Review 1.  [Novel cancer treatment and the cardiovascular risk : What should cardiologists know?]

Authors:  Matthias Totzeck; Tienush Rassaf
Journal:  Herz       Date:  2020-04       Impact factor: 1.443

Review 2.  PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism.

Authors:  Hao Dong; Yihang Qi; Xiangyi Kong; Zhongzhao Wang; Yi Fang; Jing Wang
Journal:  Front Pharmacol       Date:  2022-04-19       Impact factor: 5.988

3.  Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease.

Authors:  Phillip John Leaver; Helena Sung-In Jang; Stephen Thomas Vernon; Suran Loshana Fernando
Journal:  BMJ Case Rep       Date:  2020-05-13

Review 4.  Cardiac Complications in Immune Checkpoint Inhibition Therapy.

Authors:  Kazuko Tajiri; Masaki Ieda
Journal:  Front Cardiovasc Med       Date:  2019-01-23

Review 5.  Cardiotoxicity from immune checkpoint inhibitors.

Authors:  Lars Michel; Tienush Rassaf; Matthias Totzeck
Journal:  Int J Cardiol Heart Vasc       Date:  2019-09-07

Review 6.  Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management.

Authors:  Yu-Wen Zhou; Ya-Juan Zhu; Man-Ni Wang; Yao Xie; Chao-Yue Chen; Tao Zhang; Fan Xia; Zhen-Yu Ding; Ji-Yan Liu
Journal:  Front Pharmacol       Date:  2019-11-29       Impact factor: 5.810

7.  Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems.

Authors:  Rulan Ma; Quanziang Wang; Deyu Meng; Kang Li; Yong Zhang
Journal:  BMC Cancer       Date:  2021-01-07       Impact factor: 4.430

8.  Prediction of major adverse cardiac events is the first critical task in the management of immune checkpoint inhibitor-associated myocarditis.

Authors:  Yan Xu; Yanjun Song; Xiaoyan Liu; Yuequan Shi; Yingxian Liu; Hao Qian; Xiaoxing Gao; Minjiang Chen; Ruili Pan; Jing Zhao; Wei Zhong; Wei Wu; Mengzhao Wang
Journal:  Cancer Commun (Lond)       Date:  2022-06-09

9.  Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis.

Authors:  Lili Zhang; Magid Awadalla; Syed S Mahmood; Anju Nohria; Malek Z O Hassan; Franck Thuny; Daniel A Zlotoff; Sean P Murphy; James R Stone; Doll Lauren Alexandra Golden; Raza M Alvi; Adam Rokicki; Maeve Jones-O'Connor; Justine V Cohen; Lucie M Heinzerling; Connor Mulligan; Merna Armanious; Ana Barac; Brian J Forrestal; Ryan J Sullivan; Raymond Y Kwong; Eric H Yang; Rongras Damrongwatanasuk; Carol L Chen; Dipti Gupta; Michael C Kirchberger; Javid J Moslehi; Otavio R Coelho-Filho; Sarju Ganatra; Muhammad A Rizvi; Gagan Sahni; Carlo G Tocchetti; Valentina Mercurio; Michael Mahmoudi; Donald P Lawrence; Kerry L Reynolds; Jonathan W Weinsaft; A John Baksi; Stephane Ederhy; John D Groarke; Alexander R Lyon; Michael G Fradley; Paaladinesh Thavendiranathan; Tomas G Neilan
Journal:  Eur Heart J       Date:  2020-05-07       Impact factor: 35.855

10.  Pericardial effusion under nivolumab: case-reports and review of the literature.

Authors:  Anastasia Saade; Audrey Mansuet-Lupo; Jennifer Arrondeau; Constance Thibault; Mariana Mirabel; François Goldwasser; Stéphane Oudard; Laurence Weiss
Journal:  J Immunother Cancer       Date:  2019-10-18       Impact factor: 13.751
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.